Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech
Collaboration to develop a first-in-class α9/α10 nicotinic acetylcholine receptor antagonist for the treatment of chronic pain Kineta to receive undisclosed upfront payment and up to $359 million in ...